April 12 (Reuters) - Johnson & Johnson:
* INVOKANA® (CANAGLIFLOZIN) DEMONSTRATED SIGNIFICANT RENAL PROTECTIVE BENEFITS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE
* ANALYSIS SHOWING INVOKANA IMPROVED RENAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES MELLITUS WITH/AT HIGH RISK FOR CV DISEASE Source text for Eikon: Further company coverage:
